CMB International Securities  Equity Research  Company Update
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
ACCESS KEY TO OUR REPORTS ON BLOOMBERG CMBR
China Insurance Sector
Wenjie Ding PhD
Mkt Cap (RMB mn)
Avg 3 mths to (RMB mn)
52w HighLow (RMB)
Total Issued Shares (mn)
Source Bloomberg
Shareholding Structure
Central Huijin Investment
China Baowu Steel Group
Source HKEx
Source Bloomberg
12-mth Price Performance
Source Bloomberg
Auditor Ernst  Young
uncertainties  2 Jul 2019
Strong FYRP growth in 1Q19  29
NBV margin expansion driven by
product optimization  22 Mar
Investor day takeaway  7 Dec
SHSZ300 (rebased)
HOLD (Maintain)
(Previous TP
UpDownside
NCI released 1H19 results on 28 Aug GWP increased 90% YoY to RMB 74bn
and net profit surged 818% YoY to RMB 105bn thanks to tax savings and quality
growth Net investment yield maintained at 50% YoY while total investment yield
declined 01ppt to 47% because of impairment loss Embedded value rose 105%
YoY to RMB 6136 per share Overall speaking the Company went through
management team transition and business lull in 1H19 However clarified
strategy will likely lead to better 2H19 and current valuation is attractive
 NBV declined 87% YoY in 1H19 Individual agent channel FYRP declined
21% YoY Margin pressure has been looming since 2H18 NBV margin for
both individual channel and bancassurance channel experienced decline due
51% in 2H19 narrowing NBV decline for the whole year to 22%
 Results positives 1) NII was stable at 50% backed by successful allocation
local government bond in 1H19 2) Individual agent headcount increased 43%
or 16000 from YE18 to 386000 lending support for sales force in 2H19
 Firm strategy clarified to resolve market concerns The new board and
management team has decided to 1) pursue more balanced development of
asset and liability and attach equal attention to both 2) stick to protection-
oriented products and enrich offering of pension products medical care term
life in addition to critical illness products 3) explore opportunities in long-term
savings products to meet market demand 4) enhance long-term equity
investment
 Catalysts in 2H19 1) Upgrade of critical illness products and release of
product pipelines depending on market demand 2) expanded agent team to
support sales 3) firm strategy to focus on asset-liability match
 Adjust TP to RMB 5522 Maintain HOLD Although NBV growth fell below
our forecast the Company recorded positive economic experience variances
thanks to its investment performance thus boosting EV to increase by 105%
from YE18 We adjust TP to RMB 5522 based on 40% premium to H-share TP
A-share stock is now trading at 078x FY19E PEV Maintain HOLD
(YE 31 Dec)
GWP (RMB mn)
YoY Growth (%)
Net profit (RMB mn)
EPS CHG (%)
Source Company data CMBIS estimates
New China Life (601336 CH)
Clearer firm strategy in 2H19
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
Figure 1 1H19 results
Gross written premiums and policy fees
Less premiums ceded out
Net written premiums and policy fees
Net change in unearned premiums liabilities
Net premiums earned and policy fees
Insurance benefits and claims
Claims and net change in outstanding claims liabilities
Life insurance death and other benefits
Increase in long-term insurance contract liabilities
Policyholder dividends resulting from participation in profits
Investment contract benefits
Commission and brokerage expenses
Administrative expenses
Total benefits claims and expenses
Share of profits from associatesJVs
Non-controlling interests
Source Company data CMBIS estimates
Figure 2 Revision of forecast
Source Company data CMBIS estimates
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
Figure 3 A-share PEV
Source Company data CMBIS estimates
Figure 4 AH premium
Source Company data CMBIS estimates
Figure 5 GWP growth cumulative YoY
Source Company data CMBIS estimates
Figure 6 GWP growth monthly YoY
Source Company data CMBIS estimates
PEV (A-share)
YoY Grow th
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
YE 31 Dec (RMB mn)
FY17A FY18A FY19E FY20E FY21E  YE 31 Dec (RMB mn)
FY17A FY18A FY19E FY20E FY21E
Gross written premium
152667  Growth (%)
149746  GWP growth
983  Net profit growth
188953  EV growth
Insurance claims and reserves
(102481) (109842) (118630) (122172) (129439)  Total investment yield
(20665)  Investment assets growth
Other operating expenses
(134334) (140755) (151899) (160184) (170077)  Underwriting (%)
400  Bancassurance FYRP growth
(882)  Agent FYRPFYRP
Pre-tax profit
18394  Renewal growth
(4528)  Renewaloverall GWP
Less Minority interests
1  NBV （RMB mn）
13865  NBV growth
NBV margin (APE)
YE 31 Dec (RMB mn)
FY17A FY18A FY19E FY20E FY21E  Returns (%)
908054  RoEV
948987  Solvency (%)
Insurance liabilities
723556  Comprehensive solvency ratio
846416  Per share
Shareholders equity
102564  DPS (RMB)
7  EVPS (RMB)
102571  BVPS (RMB)
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
Disclosures  Disclaimers
Analyst Certification
The research analyst who is primary responsible for the content of this research report in whole or in part certifies that with respect to the securities
or issuer that the analyst covered in this report (1) all of the views expressed accurately reflect his or her personal views about the subject securities
in this report
Besides the analyst confirms that neither the analyst nor hisher associates (as defined in the code of conduct issued by The Hong Kong Securities
and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue
of this report (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report (3) serve
covered in this report
 Stock with potential return of over 15% over next 12 months
 Stock with potential return of 15% to -10% over next 12 months
 Stock with potential loss of over 10% over next 12 months
 Stock is not rated by CMBIS
OUTPERFORM                     Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM             Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM                 Industry expected to underperform the relevant broad market benchmark over next 12 months
CMB International Securities Limited
Address 45F Champion Tower 3 Garden Road Hong Kong Tel (852) 3900 0888   Fax (852) 3900 0800
CMB International Securities Limited (CMBIS) is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary
of China Merchants Bank)
Important Disclosures
There are risks involved in transacting in any securities  The information contained in this report may not be suitable for the purposes of all investors
CMBIS does not provide individually tailored investment advice This report has been prepared without regard to the individual investment objectives
financial position or special requirements  Past performance has no indication of future performance and actual events may differ materially from
that which is contained in the report  The value of and returns from any investments are uncertain and are not guaranteed and may fluctuate as a
independently evaluate particular investments and strategies and encourages investors to consult with a professional financial advisor in order to
make their own investment decisions
This report or any information contained herein have been prepared by the CMBIS solely for the purpose of supplying information to the clients of
CMBIS or its affiliate(s) to whom it is distributed  This report is not and should not be construed as an offer or solicitation to buy or sell any security
or any interest in securities or enter into any transaction  Neither CMBIS nor any of its affiliates shareholders agents consultants directors officers
or employees shall be liable for any loss damage or expense whatsoever whether direct or consequential incurred in relying on the information
contained in this report  Anyone making use of the information contained in this report does so entirely at their own risk
The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available
CMBIS provides the information advices and forecasts on an AS IS basis  The information and contents are subject to change without notice
CMBIS may issue other publications having information and or conclusions different from this report  These publications reflect different assumption
andor on behalf of its clients from time to time Investors should assume that CMBIS does or seeks to have investment banking or other business
the objectivity of this report and CMBIS will not assume any responsibility in respect thereof This report is for the use of intended recipients only
and this publication may not be reproduced reprinted sold redistributed or published in whole or in part for any purpose without prior written
consent of CMBIS
For recipients of this document in the United Kingdom
This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion)
Order 2005 (as amended from time to time)(The Order) or (II) are persons falling within Article 49(2) (a) to (d) (High Net Worth Companies
Unincorporated Associations etc) of the Order and may not be provided to any other person without the prior written consent of CMBIS
This report is intended for distribution in the United States to major US institutional investors as defined in Rule 15a-6 under the US Securities
Exchange Act of 1934 and may not be furnished to any other person in the United States Each major US institutional investor that receives a copy
of this research report by its acceptance hereof represents and agrees that it shall not distribute or provide this research report to any other person
For recipients of this document in Singapore
This report is distributed in Singapore by CMBI (Singapore) Pte Limited (CMBISG) (Company Regn No 201731928D) an Exempt Financial Adviser
as defined in the Financial Advisers Act (Cap 110) of Singapore and regulated by the Monetary Authority of Singapore CMBISG may distribute
reports produced by its respective foreign entities affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of
the Financial Advisers Regulations Where the report is distributed in Singapore to a person who is not an Accredited Investor Expert Investor or
an Institutional Investor as defined in the Securities and Futures Act (Cap 289) of Singapore CMBISG accepts legal responsibility for the contents
of the report to such persons only to the extent required by law Singapore recipients should contact CMBISG at 65 6350 4400 for matters arising
from or in connection with the report